Cargando…
1741. A Phase 4, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxelis™ in Healthy Children Previously Vaccinated With a 2-Dose Primary Infant Series of Either Vaxelis™ or Hexyon™ (V419-016)
BACKGROUND: Vaxelis™ is a hexavalent combination vaccine (HCV) indicated in infants and toddlers for the prevention of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive disease due to Haemophilus influenzae type b. In practice, switching between HCVs during the childhood vacci...
Autores principales: | Guerra, Andrea, Costantino, Claudio, Martinon-Torres, Federico, Westerholt, Soeren, Lambeth, Courtney, Chen, Ziqiang, Lumley, Jessie, Johnson, David, Wilck, Marissa B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677302/ http://dx.doi.org/10.1093/ofid/ofad500.1572 |
Ejemplares similares
-
HealVax
por: Foerster, John, et al.
Publicado: (2018) -
To vax or not to vax: Predictors of anti-vax attitudes and COVID-19 vaccine hesitancy prior to widespread vaccine availability
por: Roberts, Hannah A., et al.
Publicado: (2022) -
Safety and immunogenicity of a fully-liquid DTaP-IPV-Hib-HepB vaccine (Vaxelis™) in premature infants
por: Wilck, Marissa B., et al.
Publicado: (2020) -
VAX Software Overview
por: DELPHI Collaboration
Publicado: (1982) -
Central VAX upgrade
Publicado: (1987)